For example, blockade of the PR may be quite effective for the subpopulation of ER+ breast cancers identified by Fuqua and colleagues [8] that are PR-A-rich and show a very poor disease-free survival rate after antiestrogen therapy. This evidence concerns the gene PGR and breast carcinoma.